Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.

School of Health Sciences, RMIT University, Melbourne, Victoria, Australia.
Clinical Pharmacokinetics (Impact Factor: 5.49). 01/2009; 48(12):761-804. DOI: 10.2165/11318070-000000000-00000
Source: PubMed

ABSTRACT Part I of this article discussed the potential functional importance of genetic mutations and alleles of the human cytochrome P450 2D6 (CYP2D6) gene. The impact of CYP2D6 polymorphisms on the clearance of and response to a series of cardiovascular drugs was addressed. Since CYP2D6 plays a major role in the metabolism of a large number of other drugs, Part II of the article highlights the impact of CYP2D6 polymorphisms on the response to other groups of clinically used drugs. Although clinical studies have observed a gene-dose effect for some tricyclic antidepressants, it is difficult to establish clear relationships of their pharmacokinetics and pharmacodynamic parameters to genetic variations of CYP2D6; therefore, dosage adjustment based on the CYP2D6 phenotype cannot be recommended at present. There is initial evidence for a gene-dose effect on commonly used selective serotonin reuptake inhibitors (SSRIs), but data on the effect of the CYP2D6 genotype/phenotype on the response to SSRIs and their adverse effects are scanty. Therefore, recommendations for dose adjustment of prescribed SSRIs based on the CYP2D6 genotype/phenotype may be premature. A number of clinical studies have indicated that there are significant relationships between the CYP2D6 genotype and steady-state concentrations of perphenazine, zuclopenthixol, risperidone and haloperidol. However, findings on the relationships between the CYP2D6 genotype and parkinsonism or tardive dyskinesia treatment with traditional antipsychotics are conflicting, probably because of small sample size, inclusion of antipsychotics with variable CYP2D6 metabolism, and co-medication. CYP2D6 phenotyping and genotyping appear to be useful in predicting steady-state concentrations of some classical antipsychotic drugs, but their usefulness in predicting clinical effects must be explored. Therapeutic drug monitoring has been strongly recommended for many antipsychotics, including haloperidol, chlorpromazine, fluphenazine, perphenazine, risperidone and thioridazine, which are all metabolized by CYP2D6. It is possible to merge therapeutic drug monitoring and pharmacogenetic testing for CYP2D6 into clinical practice. There is a clear gene-dose effect on the formation of O-demethylated metabolites from multiple opioids, but the clinical significance of this may be minimal, as the analgesic effect is not altered in poor metabolizers (PMs). Genetically caused inactivity of CYP2D6 renders codeine ineffective owing to lack of morphine formation, decreases the efficacy of tramadol owing to reduced formation of the active O-desmethyl-tramadol and reduces the clearance of methadone. Genetically precipitated drug interactions might render a standard opioid dose toxic. Because of the important role of CYP2D6 in tamoxifen metabolism and activation, PMs are likely to exhibit therapeutic failure, and ultrarapid metabolizers (UMs) are likely to experience adverse effects and toxicities. There is a clear gene-concentration effect for the formation of endoxifen and 4-OH-tamoxifen. Tamoxifen-treated cancer patients carrying CYP2D6*4, *5, *10, or *41 associated with significantly decreased formation of antiestrogenic metabolites had significantly more recurrences of breast cancer and shorter relapse-free periods. Many studies have identified the genetic CYP2D6 status as an independent predictor of the outcome of tamoxifen treatment in women with breast cancer, but others have not observed this relationship. Thus, more favourable tamoxifen treatment seems to be feasible through a priori genetic assessment of CYP2D6, and proper dose adjustment may be needed when the CYP2D6 genotype is determined in a patient. Dolasetron, ondansetron and tropisetron, all in part metabolized by CYP2D6, are less effective in UMs than in other patients. Overall, there is a strong gene-concentration relationship only for tropisetron. CYP2D6 genotype screening prior to antiemetic treatment may allow for modification of antiemetic dosing. An alternative is to use a serotonin agent that is metabolized independently of CYP2D6, such as granisetron, which would obviate the need for genotyping and may lead to an improved drug response. To date, the functional impact of most CYP2D6 alleles has not been systematically assessed for most clinically important drugs that are mainly metabolized by CYP2D6, though some initial evidence has been identified for a very limited number of drugs. The majority of reported in vivo pharmacogenetic data on CYP2D6 are from single-dose and steady-state pharmacokinetic studies of a small number of drugs. Pharmacodynamic data on CYP2D6 polymorphisms are scanty for most drug studies. Given that genotype testing for CYP2D6 is not routinely performed in clinical practice and there is uncertainty regarding genotype-phenotype, gene-concentration and gene-dose relationships, further prospective studies on the clinical impact of CYP2D6-dependent metabolism of drugs are warranted in large cohorts.

1 Bookmark
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Time dependent variability of ECG in Brugada Syndrome (BrS) could influence interpretation of provocative testing. to characterize the ECG changes during and after flecainide infusion. We studied 59 consecutive patients. The ECG was continuously analyzed during the first 30 minutes of the provocative testing and a single ECG was performed 60 minutes after. We analyzed CYP2D6 and CYP3A5 variants affecting flecainide metabolism and performed blinded measurements at lead II. At baseline, the distribution of ECG patterns was: type II in 31 patients (53%), type III in 15 (25%) and normal ECG in 13 (22%). The percentage of responders, because of induction of type I ECG, progressively increased with longer recording time periods (10 minutes 6.8% vs. 20-30 minutes 11.9% vs. 90 minutes 18.6%; p<0.01). Four patients presented a late response, evidenced 90 minutes after the beginning of the provocative testing. QRS width differentially increased between responders and non-responders (p<0.01), with a maximum QRS width of 110 ms during the first 30 minutes being effective for identifying possible late responders (sensitivity of 100%, specificity of 85.6%, positive predictive value of 88% and negative predictive value of 100%). The incidence of CYP2D6 variants was lower in late responders than in early or delayed responders (0% vs. 75% vs. 100%; p=0.04), while a homogeneous distribution of CYP3A5*3/*3 was observed in our population. Response to flecainide exhibits a time dependent variability regarding ECG patterns and intervals. Longer periods of recording increases the recognition probability of the type I ECG. Copyright © 2014. Published by Elsevier Inc.
    Heart rhythm: the official journal of the Heart Rhythm Society 10/2014; · 4.56 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The CYP2D6 enzyme is one of the most important members of the cytochrome P450 superfamily. This enzyme metabolizes approximately 25% of currently prescribed medications. The CYP2D6 gene presents a high allele heterogeneity that determines great inter-individual variation. The aim of this study was to evaluate the variability of CYP2D6 alleles, genotypes and predicted phenotypes in Brazilians. Eleven single nucleotide polymorphisms and CYP2D6 duplications/multiplications were genotyped by TaqMan assays in 1020 individuals from North, Northeast, South, and Southeast Brazil. Eighteen CYP2D6 alleles were identified in the Brazilian population. The CYP2D6*1 and CYP2D6*2 alleles were the most frequent and widely distributed in different geographical regions of Brazil. The highest number of CYPD6 alleles observed was six and the frequency of individuals with more than two copies ranged from 6.3% (in Southern Brazil) to 10.2% (Northern Brazil). The analysis of molecular variance showed that CYP2D6 is homogeneously distributed across different Brazilian regions and most of the differences can be attributed to inter-individual differences. The most frequent predicted metabolic status was EM (83.5%). Overall 2.5% and 3.7% of Brazilians were PMs and UMs respectively. Genomic ancestry proportions differ only in the prevalence of intermediate metabolizers. The IM predicted phenotype is associated with a higher proportion of African ancestry and a lower proportion of European ancestry in Brazilians. PM and UM classes did not vary among regions and/or ancestry proportions therefore unique CYP2D6 testing guidelines for Brazilians are possible and could potentially avoid ineffective or adverse events outcomes due to drug prescriptions.
    PLoS ONE 10/2014; 9(10):e110691. · 3.53 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The introduction of antipsychotic medication in the 1950s forever changed the outlook on the treatment of schizo-phrenia, although there is still a large proportion of patients who do not reach functional recovery. At least 30% of patients do not respond to clozapine, the tricyclic dibenzo-diazepine with complex pharmacological actions, which was proven to be more effective than any other antipsy-chotic in the treatment of schizophrenia. According to most of the therapeutic guidelines for schizophrenia, cloza-pine is the third line therapy for patients who did not respond to other antipsychotics. Large inter-individual vari-ability exists for clozapine bioavailability and plasma steady-state concentrations and clearance. Clozapine is metabo-lized by the cytochrome P450 oxidase enzyme family (CYP450). Cytochrome P450 1A2 (CYP1A2), which is polymorphically expressed in humans, is the main enzyme of clozapine metabolism. This case report addresses the influence of CYP1A2*1F genetic polymorphism on cloza -pine metabolism, explains the primary non-response of a young patient with schizophrenia due to increased gene expression in homozygous genotype *1F/*1F (increased metabolism of clozapine) and underlies the importance of personalizing schizophrenia treatment by means of genetic and other molecular tools, at least in the cases of »treat-ment resistance«. Krataksadaj Po~etak primene antipsihotika pedesetih godina pro{log veka zauvek je promenio perspektivu le~enja shizofrenije, mada zna~ajan broj pacijenata sa ovom bole{}u jo{ uvek nepostìe funkcionalni oporavak. Klozapin, tricikli~ni di -ben zodijazepin sa kompleksnim farmakolo{kim profilom, koji se u tretmanu shizofrenije pokazao efikasnijim od osta -lih antipsihotika, uglavnom je tre}a linija terapijskog izbora. Me|utim, u najmanje 30% slu~ajeva obolelih od shizofreni-je stanje se ne pobolj{ava ni na terapiji klozapinom, pa se zbog toga pristupa polifarmaciji i odstupa od racionalne primene psihofarmaka. Postoji velika interindividualna vari -ja bilnost ubioraspolòivosti klozapina, stabilnoj koncentra -ciji u plazmi i njegovom klirensu. Klozapin se metaboli{e preko sistema citohrom P450 oksidaza (CYP450). Cito -hrom P450 1A2 (CYP1A2), koji se u humanoj populaciji odlikuje genskim polimorfizmima, glavni je enzim u meta -bolizmu klozapina. Aktuelni prikaz slu~aja ilustruje uticaj polimorfizma CYP1A2*1F na metabolizam klozapina, gde je primarni izostanak odgovora na terapiju kod mlade paci-jentkinje sa shizofrenijom obja{njen pove}anjem ekspresije gena kod homozigotnog genotipa *1F/*1F (povi{en meta -bolizam klozapina), i nagla{ava zna~aj personalizacije tret-mana shizofrenije uz pomo} genetike i drugih molekularnih parametara, posebno u slu~ajevima »terapo-rezistence«.
    12/2014; 33(33):1-5.